# NCT06225427 (NCT06225427)

> Gilteritinib for the Treatment of ALK NSCLC

No report yet. It can be ordered.

- Drugs tested: gilteritinib
- Indication: ALK-positive stage IV non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06225427
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: University of Michigan Rogel Cancer Center
- Conditions: Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8
- Interventions: Biopsy; Biospecimen Collection; Computed Tomography; Echocardiography; Gilteritinib; Magnetic Resonance Imaging; Questionnaire Administration
- Enrollment: 30
- Primary outcome: Incidence of adverse events
- Primary outcome: Dose-limiting toxicities (DLT)

## Indexed commentary on NCT06225427 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct06225427